Neumora Therapeutics is trading 11.2% lower at $0.60, with no verified company-specific catalyst identified. - No new company announcement or clearly linked catalyst for the September 30, 2026, decline surfaced in available searches. - The investor-relations press-release listing shows August 14, 2026, as its latest release. - Broader market context was positive, with the S&P 500 and Nasdaq higher; the reason for the decline remains unclear.